To conduct a cost-effectiveness analysis comparing the addition of memantine to standard care (that is, without acetylcholinesterase inhibitors) with standard care alone in moderate-to-severe Alzheimer disease (AD) in Canada.
A lzheimer disease is a neurodegenerative disorder with characteristic clinical features of cognitive impairment and increasing functional impairment. AD prevalence increases with age, affecting 6% to 8% of individuals older than age 65 years 1 and doubling every 5 years after age 60; therefore, an estimated 30% of the population older than 85 years has AD. Projections from the population-based CSHA estimated 279 040 cases of AD in Canada in 2005. 2, 3 Beyond the impact on a patient living with AD, as the disease becomes more severe, there is an increasing need for daily life care (primarily supervision, direction, and attention) as well as for help with basic and instrumental ADL. 4 Residential care is required for an increasing proportion of patients as the disease progresses. Although supportive community programs can provide some help for patients who remain living in the community, a large burden of care remains with informal caregivers supplemented with support and relief programs. The need for care is strongly related to the severity or stage of disease progression. 4 As well as supportive care, usual treatment for AD can include symptomatic treatment with antidepressant and anxiolytic agents. For patients with mild-to-moderate AD, AChEIs have been shown to be beneficial and are indicated in Canada and many other countries.
Memantine is a moderate-affinity uncompetitive N-methyl-D-aspartic acid antagonist approved in Canada for the symptomatic treatment of patients with moderateto-severe AD. 2 It is used in clinical practice as monotherapy or in combination with AChEIs. A recent Cochrane review 5 of memantine concluded that memantine caused a clinically noticeable reduction in deterioration over 28 weeks, compared with placebo, in patients with moderate-to-severe AD. This was supported by less functional and cognitive deterioration.
As AD prevalence increases with an aging population, there is growing concern about the burden and cost of this disease, and in the current health care environment, it is important that new therapies demonstrate cost-effectiveness. Although several studies have demonstrated the cost-effectiveness of memantine, compared with no pharmacotherapy, in various European countries, 1, 6, 7 no such study had been conducted for Canada. The current study provides an estimate for the Canadian health care setting of the cost-effectiveness of memantine monotherapy, compared with no pharmacotherapy, for patients with moderate-to-severe AD.
Methods
This cost-effectiveness study evaluates 2-year clinical outcomes in terms of additional time living independently and QALYs, as well as cost from a societal perspective associated with adding memantine to standard supportive and symptomatic care, comparing it with standard care alone for patients with moderate-to-severe AD. Standard care does not include the use of AChEIs because, although shown beneficial in mild-to-moderate AD, they are not indicated for treatment of severe AD in Canada. Primary outcomes were QALYs and costs, and secondary outcome was time spent not in complete dependence.
Model Structure
A Markov model was constructed to simulate progression over 2 years with health states based on dependence in ADL (that is, complete dependence or not) and AD severity (moderate or severe). Natural mortality was equal across groups.
A 2-year time horizon, appropriate for a chronic progressive disease with low life expectancy, 8, 9 and a 6-month Markov cycle length were used, according to clinical practice and consistent with duration of the clinical trials.
In each of four 6-month cycles, a patient was in 1 of 5 possible health states: moderate (MMSE score 10 to 19), not completely dependent in ADL; moderate, completely dependent; severe (MMSE score < 10), not completely dependent; severe, completely dependent; and deceased. In any 6-month cycle-for example, for a patient with moderate AD but not completely dependent at the cycle start, and who does not die during this cycle-there is a probability of progressing to severe dementia and a probability of progressing to complete dependence. In each 6-month period, we assessed QALYs and societal costs on the basis of dementia severity and dependence.
The model was developed from a previously published model, 1 with additional data sources used to provide stable estimates of clinical transition probabilities. The model was implemented with Data 4.0 software, 10 and independently verified twice. Results were identical for nonstochastic analyses and similar for stochastic analyses, although programming was different. One-way and probabilistic sensitivity analyses for key model parameters were conducted. 
Data Sources
The initial distributions of severity and dependence states, mortality rate, and health resource use by severity and dependence levels were obtained from data of the CSHA, 11 a Canadian population-based survey conducted in 1991-1992 with subsequent survey waves in 1996-1997 and 2001-2002, which assessed survival. Survey participants diagnosed with possible or probable AD with an MMSE score £ 19 (moderate or severe dementia) were included in the analysis.
Probabilities of progression in severity and dependence with standard care were obtained from 1107 patients with complete data in placebo arms of all relevant studies of memantine compared with placebo in this indication. [12] [13] [14] [15] [16] All the relevant studies included one study not published but with data publicly available through a registry of all completed clinical trials of memantine. 16 Including all relevant data, whether or not published, is consistent with recommended methods for metaanalyses and Cochrane reviews. This provides an estimate free of publication bias 17 and also allows the greatest available sample size to provide stable estimates. All trials had a 24-week duration. Since MMSE was assessed at baseline, but was not available at 6 months in most studies, we obtained severity categories by mapping the Severe Impairment Battery or the Alzheimer's Disease Assessment Scale-Cognitive subscale to the MMSE, using linear regression. 18 We defined dependence health states on the basis of CSHA data, using a previously described cluster analysis method. 19 Using data for 7 basic and 7 instrumental ADL tasks, each of which was scored 0 ("completely unable") to 2 ("no help needed"), we identified 2 groups (clusters) of patients. The first group (complete dependence) had severe deterioration in both basic functions (mean 2.9, SD 2.3 on a 0-to-14 scale) and instrumental functions (mean 0.5, SD 0.9). The second group (not complete dependence) had, on average, good basic function (mean 12.1, SD 1.8), although individual members might have had low scores for basic functions and poor instrumental functioning (mean 5.3, SD 4.1).
The cluster analysis procedure was reproduced on clinical trial data to determine dependence categories for these patients; for the standard care arm, probabilities of transition between dependence states were also determined from these data, within severity levels.
Memantine's effectiveness against severity progression and its effectiveness against progression in dependence within severity level were superimposed by means of logistic regression to calculate ORs consistent with methodology guidelines for modelling 20 ; the pooled data of these same studies were used for this calculation. Since information on memantine's effectiveness was available for 1 year, based on the 26-week clinical trial and 6-month follow-up, 16 consistent with current guidelines for economic evaluation, 21 memantine's effectiveness was assumed to last for 2 cycles (1 year). After the second cycle, the same transition probabilities as in the standard care arm were applied.
Death probability common for all health states and treatments was computed from the 5-year follow-up survival data of the CSHA survey, 22 adjusted to reflect that patients with AD have 2.5 times higher mortality than age-adjusted control subjects. 23 Utilities, or community preference values for dependency health states, were based on functional and QOL data obtained from a UK cohort study of 224 AD patients, translated into EQ-5D utility values. This study found that dependency was the greatest factor affecting utility. 24, 25 Health resource use and societal cost of care for the 6-month Markov cycle length were estimated by levels of disease severity and dependence on the basis of data from the CSHA, 26 with frequencies of resource use updated to reflect current practice and unit prices. The initial CSHA survey included caregiver interviews reporting the time required for help with basic and instrumental ADL, outpatient medication use, and use of the following community supportive services: homemaking or help with patient care, meal delivery, home nursing care, physiotherapy, occupational therapy, podiatry, chiropractic, day centre, respite stay in nursing home, and caregiver use of counselling or a support group. Frequencies of community service use were updated by consultation with community service programs, providing administrative data on average frequency of use as well as clinical opinion on allowed limits of use. For patients living at home, the frequency of community service use was assumed not to differ on the basis of cognitive impairment or dependence.
Current clinical practice for treatment monitoring and typical medications and regimens for those who reported use of medications related to AD (antidepressants, anxiolytics, and antipsychotics) were assessed according to consensus treatment guidelines 27 and clinical expert opinion. Typical antidepressant use was assumed to be a selective serotonin reuptake inhibitor agent because older antidepressants are no longer recommended for use in the elderly. The typical antipsychotic assumed for treatment of behavioural and psychological symptoms in dementia was risperidone, selected as the least costly of the most frequently prescribed neuroleptics, again because older neuroleptic agents are no longer recommended for the elderly. Any antiparkinsonian agent use reported in the survey was assumed to be related to older neuroleptic agents such as haloperidol, and no cost was included in our analysis.
The cost of memantine was estimated from the prescribed dosage. Since, in usual practice, a physician would treat with memantine until the patient was not receiving clinical benefit, and this would be determined after the patient had a period of time with no clinical response, the cost of memantine was continued for a third 6-month cycle. A physician visit every 12 weeks for treatment monitoring was assumed in all patients. 27 Unit prices were obtained from 2005 current standard Ontario cost sources. Total care time reported by caregivers other than paid or institutional caregivers for care with basic and instrumental ADL was summed, as was net supervision time after 
Analyses
After application of the half-cycle correction to both health outcomes and costs for each treatment alternative, we calculated costs, time in complete dependence, and total QALYs per cycle, summed across the time frame; we also assessed incremental differences in cost, time in complete dependence, and QALYs. Cost-effectiveness was calculated as incremental cost per QALY gained. We conducted 1-way sensitivity analyses, using 95%CI of the treatment effect (OR) of memantine on progression in severity and dependency and alternative discount rates of 0% and 3%. A worst-case scenario was included in which patients received memantine treatment and incurred the cost for the full 2 years but in which the treatment effect only lasted for 6 months. We conducted probabilistic sensitivity analyses to estimate uncertainty in cost-effectiveness, using Monte-Carlo simulation with input parameters (transition probabilities, treatment effectiveness, costs, and QALYs) having a priori distributions (beta, log-normal, gamma, and truncated normal, respectively). The Monte-Carlo simulation was also used to compute the cost-effectiveness acceptability curve of memantine and, in particular, the predefined probabilities 29 that memantine is cost saving, that memantine is cost-effective given a willingness to pay of $20 000 per QALY gained, and that memantine is cost-effective given a willingness to pay of $100 000 per QALY gained.
Results
Model parameters for standard care transition probabilities and health state utility are shown in Table 1 . By logistic regression, memantine's impact on the probability of having moderately severe AD adjusted on initial severity gave an OR of 1.384 (P = 0.1226; 95%CI, 0.916 to 2.092), and its impact on the probability of being not completely dependent adjusted for initial severity and dependence gave an OR of 1.557 (P = 0.0249; 95%CI, 1.057 to 2.292). The price for memantine was $4.59 daily. Total societal costs for supportive and symptomatic treatment, including memantine therapy for patients starting treatment in each of the severity-dependency health states, is shown in Table 2 .
In the base case analysis (Table 3) , the memantine strategy produced an additional 1.1 months (95%CI, 0.2 to 1.92) not in complete dependence, 0.031 additional QALYs, and a cost reduction of $1276 over the 2-year evaluation period, compared with standard care alone. Memantine is therefore considered to be the dominant strategy over standard care alone because it is both more effective and less costly.
Results were reasonably robust over the sensitivity analyses conducted (Table 4 ). For the worst-case scenario, where memantine cost is included for the full 2 years but clinical benefits only last for 6 months, memantine shows 20 fewer days in complete dependence, 0.018 QALYs, an $807 cost increase over the 2-year evaluation period, and an ICER of $45 000 per QALY gained.
Probabilistic sensitivity analyses using Monte Carlo methods to simultaneously vary all inputs gave a probability of 83.3% that the strategy is cost-neutral. The probability that the memantine strategy will be adopted increases to 89.5% if decision makers have a willingness to pay $20 000 per QALY gained and to 96.2% if decision makers have a willingness to pay $100 000 per QALY gained (Figure 1 ).
Discussion
This Canadian evaluation for patients with moderateto-severe AD not receiving AChEIs found that memantine provided 1.1 fewer months in complete dependence and 0.031 additional QALYs, compared with standard care alone. This health benefit translated into cost savings that fully offset the additional drug cost, and memantine was found to be a dominant treatment strategy over standard care.
One-way sensitivity analyses for memantine's effectiveness on severity and dependency found ICERs below $100 000 per QALY. A worst-case scenario, where memantine cost was continued for the full 2 years with effectiveness limited to 6 months, found incremental cost-effectiveness of $45 000 per QALY. Probabilistic sensitivity analyses give an 83.3% chance that memantine treatment is cost-neutral, 29 an 89.5% chance that it is cost-effective given a willingness to pay $20 000 per QALY, and a 96.2% chance given a willingness to pay $100 000 per QALY.
These results are consistent with other memantine economic evaluations conducted in Europe. 1, 6, 7 A trial-based economic evaluation associated with a 28-week pivotal trial conducted in the United States also showed 52 hours per month less caregiver time, delayed institutionalization, and lower average monthly societal cost with memantine. 12, 30 The current study population comprises patients with moderate-to-severe AD not receiving other pharmacotherapy, which is consistent with memantine's clinical indication in Canada. Memantine was not compared with AChEIs, nor did this study evaluate combination therapy with AChEIs because they are not indicated in Canada for treatment of severe AD and because the clinical trial data are primarily from within populations not treated with AChEIs. Further, published cost-effectiveness studies of AChEIs are exclusively based on cognition, 31 and any possible benefit of AChEIs on dependency could not be estimated from these studies. Considering indirect comparisons with other treatments, currently available information suggests that galantamine is more cost-effective than donepezil and rivastigmine in a Canadian setting. 32 Galantamine has been associated with an additional 0.04 QALYs over 10 years and with a cost reduction of about $800 over no therapy, 33 which is quite similar to memantine's 0.03 additional QALYs over 2 years and cost reduction of about $1200. One might expect, therefore, that memantine will also compare favourably to AChEIs in general.
The current study is based on the best available data from several different sources, combined in a model structure based on a previously published model 1 uncertainty associated with efficacy estimates compared with previous memantine economic evaluations.
The costs and benefits of memantine therapy are based on memantine use in usual practice and under conservative assumptions. From 6-month clinical trial data and 6-month follow-up, it is assumed that clinical benefit would persist for 1 year and that a further 6-month duration of memantine therapy would be required to determine that there was no clinical benefit in continuing. More frequent assessment would reduce the cost of memantine therapy after benefit was no longer being achieved and would provide better costeffectiveness. The internal validity and robustness of the model were assessed through use of stochastic simulations and sensitivity analyses conducted on the key efficacy parameters.
Model external validity was ensured through use of recent and local input data. The only exception was utility estimates, computed from a UK cohort of AD patients and based on ratings of functional ability and QOL items. The resulting utilities are close to those previously estimated for an economic model. Utility for patients requiring full-time care was similar to that for completely dependent patients in the current study (0.254 and 0.34, respectively), and utility for patients not requiring full-time care was similar to that for those not completely dependent (0.598 and 0.60, respectively The lower severity OR of 1 assumed that memantine has no effect on change in severity, and the upper severity OR used is the upper 95%CI (2.092).
Although the CSHA initial survey used to estimate the health resource use in the current study provides information about care of patients with AD more than 10 years ago, resource use intensity was updated to reflect current practice, and updated unit prices were applied. Although changes in treatment practice, such as use of less psychotropic medication, may lead to better health outcomes and reduced cost, this cannot be estimated from this data source, which was still considered the best currently available Canadian information for our study.
Conclusion
Our evaluation found that memantine monotherapy produced relevant health benefit, compared with standard care alone, with no additional costs according to a model combining information from all clinical trials data for patients not receiving AChEIs. The results are consistent with other economic evaluations of memantine conducted in Europe and the United States.
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Figure 1 Cost-effectiveness acceptability curve

Résumé : La rentabilité de la mémantine comparée aux soins réguliers dans la maladie d'Alzheimer de modérée à grave au Canada
Objectif : Mener une analyse coût-efficacité comparant l'ajout de mémantine aux soins réguliers seulement (c'est-à-dire, sans inhibiteurs d'acétylcholinestérase) dans des cas modérés à graves de maladie d'Alzheimer (MA) au Canada.
Méthodes : Un modèle de Markov de 2 ans a estimé les effets cliniques en ce qui concerne les années-personnes sans invalidité (APSI) et le temps en dépendance complète, ainsi que les coûts sociétaux de 4 cycles de 6 mois. Les états de santé ont été définis selon la gravité de la MA, évaluée à l'aide du mini-examen de l'état mental (modérée = de 10 à 19; grave < 10), selon le degré de dépendance dans les activités de la vie quotidienne, et selon la mort. Les probabilités de transition ont été estimées en combinant les données de patients souffrant de MA de modérée à grave de tous les essais cliniques pertinents. Les APSI ont été estimées d'après une étude épidémiologique britannique. La distribution initiale et l'utilisation des services médicaux et de soutien pour chaque état de santé ont été obtenues de l'Étude sur la santé et le vieillissement au Canada, auxquelles on a appliqué les estimations actuelles de fréquence d'utilisation et les prix à l'unité.
Résultats : Comparativement aux soins réguliers, la stratégie de la mémantine a épargné plus d'un mois de dépendance complète et produit 0,03 APSI additionnelle, sans frais supplémentaires. Les analyses probabilistiques de la sensibilité donnent une chance de 83,3 % que le traitement à la mémantine n'engage pas de coûts, une chance de 89,5 % qu'il soit rentable si le décideur est disposé à payer 20 000 $ pour une APSI, et une chance de 96,2 % si l'on est prêt à payer 100 000 $ par APSI. La robustesse des résultats a été confirmée par des analyses de la sensibilité à sens unique basées sur un scénario.
Conclusions :
Notre évaluation a constaté que la monothérapie à la mémantine produisait des avantages utiles pour la santé, comparativement aux soins réguliers uniquement, sans frais additionnels. Les résultats concordent avec d'autres évaluations économiques de la mémantine menées en Europe et aux États-Unis.
